L'Oréal正在购买 10%的Galderma, 将其股份提升到20%, 随着交易在2026年初结束。 L'Oréal is buying 10% of Galderma, boosting its stake to 20%, with the deal closing in early 2026.

L'Oréal在瑞士皮肤病学公司Galderma的股份正在增加,达到20%,从EQT领导的财团获得10%的股份,这笔交易预计将在2026年初结束。 L'Oréal is increasing its stake in Swiss dermatology company Galderma to 20% by acquiring 10% from a consortium led by EQT, with the deal expected to close in early 2026. 该交易没有披露财务条款,是继Galderma自2024年3月列名以来在IPO之后的强劲表现之后进行的。 The transaction, which does not disclose financial terms, follows Galderma’s strong post-IPO performance since its March 2024 listing. L'Oréal计划为2026年年度会议提名两名董事会成员,这标志着参与程度的加深,尽管它目前没有计划进一步增加其利害关系。 L'Oréal plans to nominate two board members for the 2026 annual meeting, signaling deeper involvement, though it has no current plans to raise its stake further. L'Oréal正在推行扩大医疗皮肤科和美学的战略。 The move reflects L'Oréal’s ongoing strategy to expand in medical dermatology and aesthetics.